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osting by EAbstract For systemic drug delivery, the buccal region offers an attractive route of drug adminis-
tration. Salbutamol sulfate is a short-acting b2-adrenergic receptor agonist used for the relief of
bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease. It’s oral
bioavailability is 40% due to extensive ﬁrst pass metabolism. Salbutamol sulfate patches were pre-
pared using Eudragit L-100, HPMC, PVA and Carbopol 934 in various proportions and combina-
tions using PEG-400/PG as plasticizers. Patches were laminated on one side with a water
impermeable backing layer for unidirectional drug release. The thickness of medicated patches were
ranged between 0.23 ± 0.008 and 0.59 ± 0.007 mm and mass varied between 65.23 ± 3.3 and
117.92 ± 4.2 mg. Patches showed an increase in mass and swelling index with PEG-400 when com-
pared with PG. The surface-pH of patches ranged between 6 and 7. Formulations E7 (7.5 mL
Eudragit L-100, 15 mL HPMC K4M, 7.5 mL PVA and 2 mL PEG-400), E12 (7.5 mL Eudragit
L-100, 7.5 mL PVA, 15 mL Carbopol and 2 mL PEG-400), F7 (7.5 mL Eudragit L-100, 15 mL
HPMC K4M, 7.5 mL PVA and 2 mL PG), and F12 (7.5 mL Eudragit L-100, 7.5 mL PVA,
15 mL Carbopol and 2 mL PG) showed high folding endurance. Residence time of the tested35779274, +91 431 2407995.
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Saud University.
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208 P.V. Vasantha et al.patches ranged between 101 and 110 min. The maximum in vitro release was found to be 99.93%
over a period of 120 min for formulation F12. Data of in vitro release from patches were ﬁtted
to different kinetic models such as Higuchi and Korsmeyer–Peppas models to explain the release
proﬁle. Formulations E7 and F7 were best ﬁtted to the non-Fickian, where as formulations E12
and F12 showed Fickian/anomalous drug release. Stability studies indicated that there was no
change in the chemical and physical characteristics during the test period.
ª 2011 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Beta 2-adrenergic agonists represent an effective therapeutic
treatment option for asthma, bronchospasm and conditions
with reversible airways obstruction (including chronic obstruc-
tive pulmonary disease [COPD]). Salbutamol sulfate (SS), a
selective beta 2-adrenergic agonist and bronchodilator, is one
of the widely used drugs for the treatment of the most respira-
tory diseases arising due to airway obstruction (Kelly and
Murphy, 1992). SS is a hydrophilic drug with a dissociation
constant of (pKa) 9.2 and a log P value of 0.11. The drug
undergoes extensive ﬁrst-pass metabolism with a plasma
half-life of 4–6 h (Ahrens and Smith, 1984).
SS is readily absorbed from the GI tract and has a site-
speciﬁc absorption in the stomach and upper part of small
intestine. SS undergoes extensive metabolism via intestinal
sulfonation and ﬁrst pass metabolism in the liver, it also
undergoes degradation in the colon. Owing to these reasons,
the oral bioavailability of SS is approximately 40% (Swarbrick
and Boylon, 2002; Goldstein et al., 1987). Therefore, SS is now
rarely delivered via the oral route. It is usually given by inhala-
tion or slow intravenous infusions (Ehab and Mina, 2007).
SS is usually administered via inhaled route for direct effect
on bronchial smooth muscle. This is usually achieved through
metered dose inhalers (MDIs), nebulisers or other proprietary
delivery devices (e.g. Rotahaler or Autohaler). All these drug
delivery systems have reported to have many disadvantages like
inaccuracy of dosing (require correct actuation and inhalation
coordination to deliver accurate dose), patient compliance due
to the presence of chloro ﬂuoro carbon (CFC), cost of the prep-
aration and frequency of administration. In order to overcome
these disadvantages, in the present work, we aimed to formulate
SS mucoadhesive buccal patches. Bioadhesion is the condition
in which twomaterials, at least one of which is biological in nat-
ure, are held together for extended periods of time by interfacial
forces. If the adhesive attachment is with a mucous or mucous
membrane, the phenomenon is referred asmucoadhesion (John,
2005). The interest of mucoadhesion is to increase the intimate
contact of the dosage form at the adhesion site and to improve
the bioavailability of the drug (Chowdary and Srinivasa Rao,
2003). Over the past two decades mucoadhesion has become
an interesting topic for pharmaceutical researchers due to its po-
tential to optimize localized drug delivery, by retaining a dosage
form at the site of action or systemic delivery. Owing to the ease
of administration, the oral cavity is an attractive site for the
mucosal delivery of drugs. Through this route it is possible to
realize mucosal (local effect) and transmucosal (systemic effect)
drug administration. Buccal drug delivery involves the adminis-
tration of the desired drug through the buccal mucosal lining of
the oral cavity (Silvia et al., 2005; Nazila et al., 2005). Other than
the common advantages of novel drug delivery systems, buccal
mucosa has several speciﬁc advantages like, faster and richerblood ﬂow, lesser thickness of the buccal mucosa and
increased permeability, low enzymatic activity in the buccal mu-
cosa and versatility in designing multidirectional or unidirec-
tional release systems for local or systemic action (Punitha
and Girish, 2010).2. Materials and methods
2.1. Materials
Salbutamol sulfate (SS) was obtained as a gift sample from Dr.
Reddy’s laboratories, India. Polymers hydroxypropylmethyl cellu-
lose (HPMC), polyvinyl alcohol (PVA), and Carbopol 934p (Cp),
wereprocured fromSigmaChemicals.EudragitL-100 (95%disper-
sion) was obtained as a gift sample fromRohmPharma,Germany.
Agar, methanol, sodium saccharinate, sodium hydroxide, potas-
sium dihydrogen phosphate, polyethylene glycol 400 (PEG-400)
and propylene glycol (PG), were purchased from Merck (India).
Tween-80 was a gift sample from Sd Fine Chemicals, Bangalore,
India. Biaxially-oriented polypropylene (BOPP) ﬁlm was supplied
byPidilite, India. Pig buccalmucosawas obtained from a slaugh-
ter house. All other reagents used were of analytical grade.
2.2. Methods
2.2.1. Formulation of mucoadhesive buccal patches
Salbutamol sulfate (SS) buccal mucoadhesive patches were
prepared by the solvent casting technique (Patel et al., 2007)
using different polymer combinations of Eudragit L-100
(EU-L100), HPMC, PVA and Carbopol. The experiment
was designed using a 32 full factorial design (Design Expert,
Version 7, Stat-Ease Inc., Minneapolis, MN). Different con-
centrations of polymer solutions were mixed in speciﬁed ratios
as shown in Table 1. Eudragit L-100 (95%) was dissolved in
ethanol, HPMC in ethanol:acetone mixture (3:1 v/v) and,
PVA in water. To 5 mL of Eudragit dispersion (95%), 5 mL
of ethanol and 0.05% of tween 80 were added and mixed well
on a magnetic stirrer. To the above solution known quantities
of PVA (2% m/v) and HPMC (5% m/v) or Carbopol (1%
m/v) were added and mixed thoroughly. To this mixture,
2 mL of PG or PEG was added and mixed well on a magnetic
stirrer, at low rpm, for a period of 1 h to get a homogenous
clear, bubble free solution. To this mixture, a drug solution
corresponding to 230.4 mg was added and mixed thoroughly
to obtain uniform distribution of the drug. This solution was
then poured into a specially fabricated Teﬂon coated circular
dish (9.6 cm diameter). Patches were then dried at room tem-
perature for 2 h and were further dried for 18 h at 40 C in a
hot air oven. Finally, the patches were vacuum dried for 4 h
at room temperature in a vacuum desiccator. After careful
examination, the dried patches were removed, checked for
Table 1 Composition of various patch formulations.
Formulation Eudragit L-100
(10% m/v) (mL)
HPMC K4M
(5% m/v) (mL)
PVA (2%
m/v) (mL)
Carbopol 934P
(1% m/v) (mL)
Salbutamol
sulfate (mg)
E1 F1 10.0 10.0 10.0 10.0
E2 F2 8.5 8.5 12.8 10.0
E3 F3 7.5 7.5 15.0 10.0
E4 F4 8.5 12.8 8.5 10.0
E5 F5 7.5 11.2 11.2 10.0
E6 F6 6.6 9.9 13.3 10.0
E7 F7 7.5 15.0 7.5 10.0
E8 F8 6.6 13.3 9.9 10.0
E9 F9 6.0 12.0 12.0 10.0
E10 F10 10.0 10.0 10.0 10.0
E11 F11 8.5 8.5 12.8 10.0
E12 F12 7.5 7.5 15.0 10.0
E13 F13 8.7 12.8 8.7 10.0
E14 F14 7.5 11.2 11.2 10.0
E15 F15 6.6 9.9 13.3 10.0
E16 F16 7.5 15.0 7.5 10.0
E17 F17 6.6 13.3 9.9 10.0
E18 F18 6.0 12.0 12.0 10.0
E1–E18: plasticizer used is PEG-400; F1–F18: plasticizer used is PG.
Total volume of polymer solution added excluding plasticizer and drug solution was 30 mL.
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patches using a specially fabricated circular stainless steel
cutter. The patches were laminated on one side with a water
impermeable backing layer (Pidilite BOPP ﬁlm). The samples
were packed in aluminum foil and stored in a glass container
at room temperature.
2.2.2. Evaluation of patches
2.2.2.1. Mass uniformity, thickness and folding endurance.Mass
of the patch, thickness and folding endurance were determined
for the patches without the backing membrane. Mass unifor-
mity was tested in three different, randomly selected, individ-
ual patches from each batch using an electronic balance. The
thickness of each patch was determined using a standard screw
gauge at three different positions of the patch and the average
was calculated. Folding endurance of the patches was deter-
mined by repeatedly folding one patch at the same place till
it broke or folded up to 300 times without breaking (Khanna
et al., 1997).
2.2.2.2. Drug content. The medicated patch (without backing
membrane) was dissolved in 10 mL of simulated saliva solu-
tion (pH 6.2) for 2–3 h under occasional shaking. The resultant
solution was ﬁltered through 0.45 lm membrane ﬁlter paper.
After suitable dilution, the amount of SS present in the patch
was determined spectrophotometrically at 278 nm (Shimadzu
1800, Japan).
2.2.2.3. Measurement of surface pH. A modiﬁed method actu-
ally reported by (Bottenberg et al., 1991) was used to deter-
mine the surface pH of the buccal patches (without backing
membrane). Buccal patches were allowed to swell for 2 h on
the surface of an agar plate (prepared by dissolving 2%
(m/v) agar in warmed isotonic phosphate buffer (pH 6.8) un-
der stirring and then pouring the solution into a Petri dish till
it gelled at room temperature). The surface pH was measured
by bringing a combined glass electrode in contact with thesurface of the patch, allowing it to equilibrate for 1 min. The
average of the three readings was recorded.
2.2.2.4. Swelling studies. A drug loaded patch of (without
backing membrane), 2 cm diameter was allowed to swell on
the surface of an agar plate (prepared as described under
Section 2.2.2.3) kept in an incubator maintained at 37 C.
Measurement of the diameter of the swollen patch was carried
out at predetermined time intervals for 90 min.
Swelling index was calculated from the following equation:
SI ð%Þ ¼ ððDt DoÞ=DoÞ  100
where SI (%) is the percent swelling index, Dt is the diam-
eter of the swollen patch after time t and Do is the original
patch diameter at time zero (Patel et al., 2007).
2.2.2.5. Residence time (ex vivo mucoadhesion time). A locally
modiﬁed USP (Erweka ZT72) disintegration apparatus was
used to determine the ex vivo mucoadhesion (residence) time
(Nakamura et al., 1996). The mucosal membrane (fresh pig
buccal mucosa) was separated by removing the underlying
fat and loose tissues. The membrane was washed with distilled
water and then with simulated saliva (pH 6.2) at 37 C. Pig
cheek mucosa, 3 cm long, was glued to the surface of a glass
slide. One side of the patch was wetted with one drop of
simulated saliva (pH 6.2) and pasted to the pig buccal mucosa
by applying a light force with ﬁngertip for 20 s. The glass slide
was vertically ﬁxed to the apparatus and allowed to move up
and down so that the patch was completely immersed in the
buffer solution at the lowest point and was out at the highest
point. The beaker was ﬁlled with 800 mL of simulated saliva at
(pH 6.2) and was kept at 37 ± 1 C. The time required for the
patch to detach from the buccal mucosa was recorded as the
mucoadhesion time (mean of three determinations).
2.2.2.6. In vitro drug dissolution. USP 23 Type-2 rotating
paddle dissolution test apparatus (Electrolab, EDT-08Lx)
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(Nafee et al., 2003). The dissolution medium used was 100 mL
simulated saliva solution (pH 6.2) at 37 ± 0.5 C which was
stirred at 50 rpm. The patch of 2 cm diameter was ﬁxed on
the glass disk with the help of a cyanoacrylate adhesive. The
disk was put at the bottom of the dissolution vessel so that
the patch remained on the upper side of the disk. Samples
(4 mL) were withdrawn at pre-determined time intervals (5,
10, 15, 30, 45, 60, 90, 120, 150 and 180 min) and replaced with
equal volume of dissolution medium. The samples were ﬁltered
through 0.45 lm ﬁlter and appropriately diluted with simu-
lated saliva solution (pH 6.2) and assayed spectrophotometri-
cally at 278 nm. The mechanism of drug release from the
buccal patches was determined by ﬁnding the best ﬁt of the re-
lease data to Higuchi and Korsmeyer–Peppas plots (Mathew
et al., 2009; Higuchi, 1961).
2.2.2.7. In vitro drug permeation. The in vitro buccal permeation
of SS was studied through the pig buccal mucosa using Franz-
diffusion cell. Freshly obtained buccal mucosa wasmounted be-
tween the donor and receptor compartments so that the smooth
surface of the mucosa faced the donor compartment. The patch
was placed on the mucosa and the compartments clamped to-
gether. The donor compartment was slightly wetted with 1 mL
of simulated saliva. The receptor compartment was ﬁlled with
isotonic phosphate buffer pH 7.4. Thediffusion cell was thermo-
stated at 37 ± 0.2 C and the receptor compartment was stirred
at a rate of 100 rpm (Nafee et al., 2003). One milliliter sample
waswithdrawn at pre-determined time intervals using a butterﬂy
canula and syringe. The buffer was immediately replaced using
blank pre-warmed buffer. After ﬁltration through 0.45 lmﬁlter
and appropriate dilution the samples were analyzed for the drug
content spectrophotometrically at 278 nm.
2.2.2.8. Accelerated stability studies and stability in human
saliva. Selected patches were subjected to accelerated stability
testing by wrapping them in aluminum foil and packing them
in glass vials. These patches were kept in an incubator main-
tained at 37 ± 0.5 C and 75 ± 5% RH for 6 months.
Changes in the appearance, residence time and drug content
of the stored patches were investigated after 1, 2, 3, 5 and
6 months. The data presented were the mean of three determi-
nations. Stability of the selected patches was assessed in natu-
ral human saliva collected from healthy human adult
volunteers. Patches were placed in separate Petri dishes con-
taining 5 mL of human saliva and kept in a temperature-con-
trolled oven at 37 ± 0.2 C for 4 h. The patches were examined
for changes in color, shape and drug content.
3. Results and discussion
In the present study, buccal patches of SS were prepared with
different polymer combinations of Eudragit L-100, HPMC,
PVA, and Cp using solvent casting method. A total of 36 for-
mulations were prepared in triplicate using a 32 factorial design.
Factorial design was used only to design the experiments. PG
or PEG-400 was used as the plasticizer.
One of our major aims during the formulation step was to
avoid use of organic solvents to prevent any unwanted residual
solvent complications when the patch is used in vivo. But, due to
the presence of Eudragit L-100 dispersion, which is insoluble in
water, we used ethanol as a solvent in the formulation.However,the ratio of Eudragit L-100 dispersion to ethanol was kept to the
minimum (1:1) by using tween 80 as a surfactant. The high dry-
ing time of the patches is possibly related to the major propor-
tion of water which was used to solubilize the polymers.
Impermeable backing membrane is an essential part of buc-
cal mucoadhesive patch to obtain unidirectional drug ﬂow.
Backing membrane prevents the loss of drug at the required
site and also minimizes the exposure of other tissues to the
drug by preventing bidirectional ﬂow. Many authors have used
ethyl cellulose as the backing membrane but reports shows
that it has some permeability. Also laminating the patches with
ethyl cellulose ﬁlm was not completely successful (Mukherjee
et al., 2005; Rowe et al., 2009). Therefore, in the current study,
we have used BOPP ﬁlm as the backing membrane.
Physico-chemical characteristics of the medicated patches
are shown in Tables 2 and 3. The prepared patches were
smooth, uniform in thickness, mass and drug content. Patches
showed no visible cracks or folds. The thickness of the medi-
cated patches ranged between 0.23 ± 0.008 and
0.59 ± 0.007 mm and the mass varied between 65.23 ± 3.3
and 117.92 ± 4.2 mg, patches with PEG-400 as a plasticizer
showed increased mass. This observation could be correlated
to the high molecular weight of PEG-400 when compared to
PG. The surface pH of the patches ranged between 6 and 7
and no mucosal irritation was expected. Patches showed favor-
able drug loading which varied between 9.0 ± 0.3 and
10.05 ± 0.82 mg/2 cm2 patches (i.e. drug loading efﬁcacy of
90–100%). All the patches had satisfactory folding endurance
of >240. Formulations E7, E12, F7 and F12 showed high
folding endurance of over 300, and hence were selected for fur-
ther evaluation and characterization.
Swelling behavior of selected SS patches as a function of
time is illustrated in Fig. 1. The swelling indices of the prepared
patches were found to be moderate and varied between the for-
mulations, which could be due to the presence of the water
insoluble polymer Eudragit. It was difﬁcult to interpret the
relation between hydrophilicity of polymers and swelling index
from these results, since the patch was composed of both
hydrophilic and hydrophobic polymers. At the same time,
when we consider the fact that all tested patches contained
one part of Eudragit polymer and there by assuming that the
effect of Eudragit in swelling of the patches as common and
can be neglected, then the differences in swelling of the tested
hydrophilic polymers could be explained by the difference in
resistance of the matrix network structure (hydrogen bond)
to the movement of water molecules (Panomsuk et al., 1995).
While analyzing these observations, we should also account
for the presence of water-soluble SS which might have im-
proved the surface wetting of the matrix. The swelling indices
of the selected patches were in the following order
E12 > E7 > F12 > F7. There was a noticeable reduction in
the swelling index of patches prepared using PG as plasticizer.
The swelling indices of patches prepared with PG as plasticizer
was as low as 29 (F7) and 31 (F12) where as that of the patches
prepared by PEG as plasticizer was 41 and 35 for formulations
E12 and E7, respectively. This observation suggests that the
presence of PEG-400 would have altered the water distribution
within such systems. This would have modiﬁed the matrix
structure (Lucy et al., 1995). Even though the swelling indices
were moderate, the patches did not show any appreciable
changes in their shape and form and maintained their integrity
during the study period.
Table 2 Physico-chemical characteristics of the SS patches with PEG-400 as plastizer.
Formulation
code
Mass uniformity
(mg ± SD)a
Thickness
(mm± SD)a
Folding
endurance
(times)a
Drug content
(mg ± SD)a
Drug loading
eﬃciency (%)a
Surface pHa
E1 82.23 ± 4.3 0.55 ± 0.002 250 9.6 ± 0.6 96 ± 0.6 7.1 ± 0.05
E2 86.93 ± 3.1 0.41 ± 0.006 253 9.2 ± 0.4 92 ± 0.4 6.2 ± 0.08
E3 91.42 ± 4.4 0.42 ± 0.002 255 9.1 ± 0.52 91 ± 0.52 6.1 ± 0.12
E4 93.18 ± 2.6 0.43 ± 0.003 260 9.9 ± 0.12 99 ± 0.12 6.9 ± 0.08
E5 101.58 ± 4.5 0.42 ± 0.004 268 9.6 ± 0.87 96 ± 0.87 6.8 ± 0.04
E6 104.91 ± 6.2 0.41 ± 0.003 266 9.0 ± 0.3 90 ± 0.3 6.2 ± 0.17
E7 109.52 ± 7.2 0.48 ± 0.002 >300 9.8 ± 0.9 98 ± 0.9 6.9 ± 0.08
E8 114.28 ± 5.6 0.56 ± 0.006 272 9.0 ± 0.7 90 ± 0.7 6.8 ± 0.01
E9 117.92 ± 4.2 0.57 ± 0.007 275 9.4 ± 0.5 94 ± 0.5 6.1 ± 0.04
E10 69.98 ± 4.2 0.59 ± 0.001 255 9.3 ± 0.8 93 ± 0.8 6.5 ± 0.03
E11 77.58 ± 3.2 0.55 ± 0.002 259 9.8 ± 0.43 98 ± 0.43 6.9 ± 0.07
E12 78.99 ± 6.9 0.48 ± 0.003 >300 9.4 ± 0.92 94 ± 0.92 7.1 ± 0.01
E13 77.32 ± 3.3 0.58 ± 0.008 262 9.1 ± 0.54 91 ± 0.54 6.9 ± 0.06
E14 81.64 ± 2.0 0.52 ± 0.009 268 9.8 ± 0.86 98 ± 0.86 6.8 ± 0.02
E15 85.24 ± 6.9 0.32 ± 0.006 273 9.1 ± 0.9 91 ± 0.9 7.0 ± 0.03
E16 81.66 ± 1.1 0.42 ± 0.007 275 9.6 ± 0.5 96 ± 0.5 7.1 ± 0.04
E17 83.01 ± 1.0 0.39 ± 0.008 274 9.4 ± 0.95 94 ± 0.95 6.8 ± 0.11
E18 84.99 ± 8.1 0.59 ± 0.002 279 9.3 ± 0.32 93 ± 0.32 6.2 ± 0.05
a Average of three determinations.
Table 3 Physico-chemical characteristics of the SS patches with PG as plastizer.
Formulation
code
Mass uniformity
(mg ± SD)a
Thickness
(mm± SD)a
Folding
endurance
(times)a
Drug content
(mg ± SD)a
Drug loading
eﬃciency (%)a
Surface
pHa
F1 78.12 ± 8.2 0.57 ± 0.005 240 10.01 ± 0.54 100 ± 0.54 6.8 ± 0.03
F2 83.28 ± 6.4 0.42 ± 0.004 245 9.8 ± 0.91 98 ± 0.91 7.0 ± 0.12
F3 86.99 ± 5.9 0.47 ± 0.008 249 9.5 ± 0.42 95 ± 0.42 6.1 ± 0.08
F4 89.78 ± 8.4 0.58 ± 0.002 252 9.4 ± 0.84 94 ± 0.84 6.9 ± 0.04
F5 97.46 ± 2.9 0.52 ± 0.009 257 9.9 ± 0.61 99 ± 0.61 7.0 ± 0.03
F6 99.52 ± 6.8 0.59 ± 0.007 254 9.2 ± 0.94 92 ± 0.94 6.9 ± 0.01
F7 103.62 ± 4.1 0.58 ± 0.005 >300 9.7 ± 0.34 97 ± 0.34 6.5 ± 0.06
F8 109.19 ± 4.8 0.51 ± 0.004 259 9.8 ± 0.74 98 ± 0.74 6.9 ± 0.12
F9 112.22 ± 2.2 0.23 ± 0.008 260 9.9 ± 0.81 99 ± 0.81 6.8 ± 0.04
F10 65.23 ± 3.3 0.47 ± 0.009 245 9.8 ± 0.72 98 ± 0.72 6.1 ± 0.08
F11 72.99 ± 4.8 0.56 ± 0.007 249 9.8 ± 0.83 98 ± 0.83 7.0 ± 0.04
F12 74.63 ± 3.9 0.59 ± 0.005 >300 9.1 ± 0.94 91 ± 0.94 6.8 ± 0.04
F13 72.99 ± 8.7 0.59 ± 0.004 252 10.05 ± 0.82 100 ± 0.82 6.1 ± 0.02
F14 76.99 ± 4.9 0.52 ± 0.009 258 9.2 ± 0.94 92 ± 0.94 7.0 ± 0.01
F15 81.89 ± 6.7 0.49 ± 0.002 263 9.18 ± 0.91 91 ± 0.91 7.1 ± 0.09
F16 77.38 ± 91 0.48 ± 0.006 259 9.01 ± 0.45 90 ± 0.45 6.2 ± 0.06
F17 79.89 ± 4.2 0.53 ± 0.005 264 9.4 ± 0.84 94 ± 0.84 6.0 ± 0.02
F18 80.99 ± 9.9 0.39 ± 0.008 265 9.08 ± 0.52 90 ± 0.52 7.1 ± 0.13
a Average of three determinations.
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residence time of the tested patches ranged between 101 and
110 min. Previous studies reported, no relation between
mucoadhesion strength and mucoadhesion time (Nafee et al.,
2003). However, none of the patches were detached from the
mucosal membrane over the study period, which indicated that
the bioadhesion of all patches was satisfactory to retain the
patch on the buccal mucosa.
In vitro release of SS from different patches is shown in
Fig. 3. All the tested formulations released >80% of the drug
within 90 min. Formulation F12 showed the maximum release
of 99.93% at the end of 120 min. Formulation E7 showedslower drug release, and showed maximum drug release of
98.99% after 150 min. We could not detect any relationship
between the drug release proﬁle and polymer composition.
The drug release proﬁle of selected patches showed an erratic
drug release, which is not ideal for controlled drug delivery sys-
tems. Controlled drug delivery systems release the drug
through a variety of complex mechanisms, and are not yet
completely deﬁned. Many of these mechanisms are classiﬁed
as either purely diffusion controlled or purely erosion con-
trolled; many others can only be interpreted as being governed
by both. The release data of the tested patches were analyzed
on the basis of Korsmeyer–Peppas equation and Higuchi
Ti
m
e 
(m
in)
Figure 2 Ex vivo mucoadhesion time. Values presented as
mean ± SD, n= 3.
Figure 1 Swelling behavior of selected SS patches. Values
presented as mean ± SD, n= 3.
Table 4 Values of R2, k and n for selected formulations.
Formulation Higuchi Korsm
R2 y k R2
E7 0.9484 0.8461x  0.5352 0.8461 0.9601
E12 0.9532 0.7335x+ 1.0874 0.7335 0.9675
F7 0.9421 0.875x  0.982 0.875 0.9548
F12 0.9547 0.7522x+ 0.7581 0.7522 0.9613
Figure 3 In vitro release of SS from different patch formulations.
Values presented as mean ± SD, n= 3.
Figure 4 In vitro permeation of SS from different patch
formulations. Values are presented as mean ± SD, n= 3.
212 P.V. Vasantha et al.kinetics. The release rates ‘k’ and ‘n’ of each model were calcu-
lated by linear regression analysis using Microsoft Excel 2003
software. Coefﬁcients of correlation (R2) were used to evaluate
the accuracy of the ﬁt (Mathew et al., 2009; Higuchi, 1961;
Korsmeyer et al., 1983; Peppas, 1985). The R2, ‘k’ and ‘n’ val-
ues are given in Table 4.
The R2 values for Higuchi and Peppas kinetic models were
calculated and compared. All the tested formulations gave
good ﬁt to the Korsmeyer–Peppas model. Formulations E12
and F12 exhibited Fickian release. Formulations E7 and F7
showed non-Fickian drug release. In non-Fickian model, the
drug release varies with time (t) according to the power law.
When swelling is predominant, drug diffusion probably occurs
through the solvent-ﬁlled pathways of the swollen patch. Ero-
sion of the matrix can also inﬂuence the drug release from this
polymer matrix. A relative contribution of erosion and diffu-
sion to the overall release mechanism is suggested. Since all
the tested patches had water soluble and water insoluble poly-
mers we could not correlate the difference in mechanism of
drug release with the polymer properties.
The in vitro permeation of SS from different patches is
shown in Fig. 4. The drug permeation was fast and showed
the similar proﬁle as that of the drug release. From formula-
tion F12 showed a maximum drug permeation of 97.91% over
a period of 180 min followed by E12 (97.52% at 120 min), F7
(96.98 at 120 min) and E7 (96.41 at 150 min). The results of
drug permeation from buccal patches of SS through the por-
cine buccal mucosa reveal that SS was released from the for-
mulations and permeated through the porcine buccal
membrane and hence could possibly permeate through the hu-
man buccal membrane. There was a good correlation between
the in vitro drug release and in vitro drug permeation study re-
sults. The correlation between in vitro release and in vitro per-
meation is shown in Fig. 5. The correlation coefﬁcient (R2)
between the drug permeation and drug release was as follows.eyer–Peppas Mechanism of drug release
y n
0.552x  1.2179 0.552 Non-Fickian
0.4341x  0.9342 0.4341 Fickian
0.6221x  1.3639 0.6221 Non-Fickian
0.4714x  1.0149 0.4714 Fickian
Figure 5 Correlation between in vitro release and in vitro permeation of selected SS patches.
Table 5 Physical stability characteristics of selected SS patches.
Evaluation parameter Formulation code 1st month 2nd month 3rd month 5th month 6th month
Drug content (%)* E7 9.7 ± 0.6 9.7 ± 0.8 9.6 ± 0.6 9.6 ± 0.5 9.6 ± 0.6
E12 9.3 ± 0.9 9.3 ± 0.8 9.2 ± 0.9 9.0 ± 0.2 9.0 ± 0.1
F7 9.6 ± 0.24 9.6 ± 0.34 9.5 ± 0.3 9.5 ± 0.24 9.5 ± 0.4
F12 9.1 ± 0.3 9.0 ± 0.62 9.0 ± 0.12 9.0 ± 0.9 9.0 ± 0.4
Residence time* E7 103 ± 2.9 103 ± 2.4 103 ± 3.2 101 ± 3.1 100 ± 2.5
E12 110 ± 3.2 109 ± 4.1 109 ± 4.6 107 ± 3.5 107 ± 3.9
F7 100 ± 5.5 109 ± 5.1 109 ± 6.1 109 ± 5.1 107 ± 4.9
F12 106 ± 5.1 106 ± 5.7 105 ± 4.2 105 ± 4.3 105 ± 5.2
Appearance E7 No change No change No change No change No change
E12 No change No change No change No change No change
F7 No change No change No change No change No change
F12 No change No change No change No change No change
* Average of three determinations.
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and F12 was 0.9991.
Accelerated stability study data of the medicated patches are
shown in Table 5. During and at the end of the accelerated sta-
bility study, the tested patches showed similar drug content as
observed at the beginning of the study. They also showed satis-
factory ﬂexibility and elastic properties during and at the end of
the accelerated study period. We have conducted the stability
studies in normal human saliva sincewould appropriatelymimic
the stability of drug and device in the oral cavity in vivo. No color
changes or unexpected change in the texture was observed. The
drug content of the tested patches was in the range of 9.0 ± 0.1and 9.7 ± 0.8 mg. The results of stability studies indicated that
there was no inﬂuence on the chemical and physical stability of
the formulations during the test period.4. Conclusions
Novel mucoadhesive buccal patches of SS with unidirectional
drug delivery were developed to overcome the ﬁrst-pass metab-
olism and subsequent low bioavailability of the drug. The
in vitro studies have shown that this is a potential drug delivery
system for SS with considerably good stability and release
214 P.V. Vasantha et al.proﬁle. But, future in vivo studies are warranted to conﬁrm these
results in vivo.
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